The second most common cancer among men is prostate cancer, affecting 1 in 8 men. Prostate cancer is treatable, in most cases, when the cancer remains localized to the prostate gland. But if the ...

A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in ...

Early data show promising results for cabozantinib, a new therapeutic agent for castration-resistant prostate cancer (CRPC), particularly against tumors that have metastasized to the bone. In a phase ...

A team of scientists has harnessed CRISPR technology to identify a protein that helps cancers spread to bone tissue, opening the door for potential therapies to prevent the common and painful disease ...

The American Cancer Society estimates that more than 313,780 cases of prostate cancer will be diagnosed in the United States in 2025, resulting in approximately 35,770 deaths. Bone metastasis - a ...

Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice? Bone metastases are a major cause of morbidity for men with prostate cancer. Complications of bone metastases include ...

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.

New research published Monday in the journal Cancer Cell cracked an important code in the quest to prevent metastatic cancer. “If a tumor just stayed in the breast it wouldn’t kill anybody, but tumor ...

A prospective, multicenter cancer clinical trial by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has validated an ...

Bone metastases are a major cause of morbidity for men with prostate cancer. Complications of bone metastases include pain, fractures, and spinal cord compression. Although they appear osteoblastic by ...